DT-061 (SMAP) Liposomes, Formulation TT-40
LipExoGen
300 mM sucrose
Description: PEGylated liposomes containing PP2A activator DT-061 (SMAP). DT-061 is an activator of protein phosphatase 2A (PP2A). PP2A regulates many cellular signaling pathways including MAPK/ERK, Wnt/β-catenin, Akt/mTOR, GSK3β, p53/apoptosis, cell cycle, and others. This product can be used in vitro or in vivo for studying the effects of PP2A activation and could be applied to preclinical therapy of KRAS-mutant and MYC-driven tumors. The liposomes are PEGylated for optimal in vivo performance. For preclinical research use only.
4.0 mg/mL
PP2A pathway (regulates MAPK/ERK, Wnt/β-catenin, Akt/mTOR, GSK3β, p53/apoptosis. cell cycle, and other pathways)
Did you look for something else?
Adavosertib Liposomes, Formulation WD4
Adavosertib Liposomes, Formulation WD4
SP600125 Liposomes, Formulation HZ12
Rocaglamide Liposomes, Formulation KHE9A
Rocaglamide Liposomes, Formulation KHE9A
Rocaglamide Liposomes, Formulation KHE9A
AZD1208 Liposomes, Formulation RB4T4
AZD1208 Liposomes, Formulation RB4T4
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
Mirdametinib (PD0325901) Liposomes, Formulation U6-2
Tanespimycin (17-AAG) Liposomes, Formulation XT28.1
Tanespimycin (17-AAG) Liposomes, Formulation XT28.1
Eganelisib (IPI-549) Liposomes, Formulation WNX5.2
